Multi-component redox system for selective and potent antineoplastic activity towards ovarian cancer cells

Area of Science:

• Oncology
• Biochemistry
• Photodynamic Therapy

Background:

• Ovarian cancer is a deadly gynecological malignancy often detected at advanced, drug-resistant stages.
• Conventional photodynamic therapy (PDT) faces limitations due to the difficulty of selectively irradiating tumor cells.
• Meso-tetra(4-N-methylpyridyl)porphine (TMPyP) is a photosensitizer with DNA affinity and reactive oxygen species (ROS) generation.

Purpose of the Study:

• To develop a novel, non-invasive therapeutic strategy for ovarian cancer.
• To create a drug combination that leverages the tumor microenvironment for cancer cell death.
• To investigate an alternative to traditional photodynamic therapy (PDT) that bypasses the need for photoactivation.

Main Methods:

• A drug combination of TMPyP, 1,5-dihydroxynaphthalene (DHN), and Fe(III) ions was formulated.
• The combination's efficacy was tested in vitro on drug-resistant and sensitive ovarian cancer cell lines.
• The mechanism of action was investigated, focusing on ROS generation and anticancer agent production in a hydrogen peroxide-rich environment.

Main Results:

• The drug combination demonstrated significant growth inhibition and cell death in ovarian cancer cells.
• The treatment was effective even in drug-resistant cell lines.
• The combination generates the anticancer agent juglone and hydroxyl radicals (ȮH) without external light activation in a hydrogen peroxide-rich environment.

Conclusions:

• The developed drug combo offers an effective, non-invasive treatment for ovarian cancer by utilizing cancer cell's endogenous hydrogen peroxide.
• This approach generates cytotoxic species, including juglone, through redox chemistry involving Fe(III) activation.
• The study presents a promising alternative to conventional PDT for treating ovarian cancer, particularly in advanced or drug-resistant cases.